Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases.
Anielle de Pina-CostaAna Carolina Rios SilvinoEdwiges Motta Dos SantosRenata Saraiva PedroJosé MoreiraGabriela Liseth UmanaAna Danielle Tavares da SilvaOtília Helena Lupi da Rosa SantosKarina Medeiros de Deus HenriquesCláudio Tadeu Daniel-RibeiroPatrícia BrasilTais Nobrega SousaAndré Machado de SiqueiraPublished in: Malaria journal (2021)
Lack of response to primaquine was associated with impaired CYP2D6 activity in three patients presenting multiple relapses followed in a non-endemic setting. Higher primaquine dosage was safe and effectively prevented relapses in two patients and should be further investigated as an option in Latin America. It is crucial to investigate the factors associated with unsuccessful radical cures and alternative therapeutic options.